You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for GT 949
GT 949 is a potent and selective EAAT2 positive allosteric modulator (EC50 = 0.26 nM). Enhances the glutamate translocation rate, with no effect on substrate interaction. Enhances glutamate uptake by cultured astrocytes by approximately 58%. Exhibits no significant effect on DAT, SERT and NET or NMDA receptors. Neuroprotective in an in vitro model of excitotoxicity.
Compound Libraries for GT 949
Technical Data for GT 949
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for GT 949
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for GT 949
The following data is based on the product molecular weight 527.66. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.9 mL||9.48 mL||18.95 mL|
|5 mM||0.38 mL||1.9 mL||3.79 mL|
|10 mM||0.19 mL||0.95 mL||1.9 mL|
|50 mM||0.04 mL||0.19 mL||0.38 mL|
References for GT 949
References are publications that support the biological activity of the product.
Kortagere et al (2018) Identification of novel allosteric modulators of glutamate transporter EAAT2. ACS Chem.Neurosci. 9 522 PMID: 29140675
Falcucci et al (2019) Novel Positive Allosteric Modulators of Glutamate Transport Have Neuroprotective Properties in an in Vitro Excitotoxic Model. ACS Chem.Neurosci. 10 3437 PMID: 31257852
If you know of a relevant reference for GT 949, please let us know.
View Related Products by Product Action
Keywords: GT 949, GT 949 supplier, GT949, selective, EAAT2, positive, allosteric, modulators, PAM, Glutamate, Transporters, 6578, Tocris Bioscience
1 Citation for GT 949
Citations are publications that use Tocris products. Selected citations for GT 949 include:
Zhang et al (2019) Müller Glial Cells Participate in Retinal Waves via Glutamate Transporters and AMPA Receptors. Cell Rep 27 2871 PMID: 31167134
Do you know of a great paper that uses GT 949 from Tocris? Please let us know.
Reviews for GT 949
There are currently no reviews for this product. Be the first to review GT 949 and earn rewards!
Have you used GT 949?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.